The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Open accessAbstract
The Wnt/beta-catenin pathway is a family of proteins that is implicated in many vital cellular functions like stem cell regeneration and organogenesis. Several intra-cellular signal transduction pathways are induced by Wnt, notably the Wnt/beta-catenin dependent pathway or canonical pathway and the non-canonical or beta-catenin-independent pathway, the latter includes the Wnt/Ca2+ and Planar Cell Polarity pathway (PCP). Wnt activation occurs at the intestinal crypt floor, and is critical to optimal maintenance of stem cells. Colorectal cancers show evidence of Wnt signaling pathway activation and this is associated with loss of function of the tumor regulator APC. Wnt activation has been observed in breast, lung, and hematopoietic malignancies and contributes to tumor recurrence. The Wnt pathway cross talks with the Notch and Sonic Hedgehog pathways, which has implications for therapeutic interventions in cancers. There are significant challenges in targeting the Wnt pathway, including finding agents that are efficacious without damaging the system of normal somatic stem cell function in cellular repair and tissue homeostasis. Here, we comprehensively review the Wnt pathway and its interactions with the Notch and Sonic Hedgehog pathways. We present the state of the field in effectors and inhibitors of Wnt signaling, including updates on clinical trials in various cancers with inhibitors of Wnt, Notch, and Sonic Hedgehog.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, J. B., Todaro, M., Merz, C., Rodermond, H., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2048 · Cited by 1,804
Linking Colorectal Cancer to Wnt Signaling
Bienz, M., & Clevers, H. (2000) · Cell · doi:10.1016/s0092-8674(00)00122-7 · Cited by 1,515
Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors
Gordon, M. D., & Nusse, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600015200 · Cited by 1,333
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
Wnt Induces LRP6 Signalosomes and Promotes Dishevelled-Dependent LRP6 Phosphorylation
Bilić, J., Huang, Y.-L., Davidson, G., Zimmermann, T., Cruciat, C.-M., Bienz, M., & Niehrs, C. (2007) · Science · doi:10.1126/science.1137065 · Cited by 934
GSK3: a multifaceted kinase in Wnt signaling
Wu, D., & Pan, W. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.10.002 · Cited by 857
Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., & Polakis, P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70226-x · Cited by 836
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., Kasibhatla, S., Schuller, A. G., Li, A. G., Cheng, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314239110 · Cited by 831
Wnt and calcium signaling: β-Catenin-independent pathways
Kohn, A. D., & Moon, R. T. (2005) · Cell Calcium · doi:10.1016/j.ceca.2005.06.022 · Cited by 730
Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent β-catenin degradation
Topol, L., Jiang, X., Choi, H., Garrett-Beal, L., Carolan, P. J., & Yang, Y. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200303158 · Cited by 724
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
Frizzled and LRP5/6 Receptors for Wnt/ -Catenin Signaling
MacDonald, B. T., & He, X. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007880 · Cited by 612
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561
Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
Khramtsov, A. I., Khramtsova, G. F., Tretiakova, M., Huo, D., Olopade, O. I., & Goss, K. H. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091125 · Cited by 509
Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., Wang, J., Doble, B., Woodgett, J., et al. (2008) · Development · doi:10.1242/dev.013540 · Cited by 492
Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene
Aoki, K., & Taketo, M. M. (2007) · Journal of Cell Science · doi:10.1242/jcs.03485 · Cited by 492
RNF43 is frequently mutated in colorectal and endometrial cancers
Giannakis, M., Hodis, E., Jasmine Mu, X., Yamauchi, M., Rosenbluh, J., Cibulskis, K., Saksena, G., Lawrence, M. S., Qian, Z. R., Nishihara, R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3127 · Cited by 470
Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers
White, B. D., Chien, A. J., & Dawson, D. W. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.001 · Cited by 469
Kurayoshi, M., Oue, N., Yamamoto, H., Kishida, M., Inoue, A., Asahara, T., Yasui, W., & Kikuchi, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2359 · Cited by 451
Krop, I., Demuth, T., Guthrie, T., Wen, P. Y., Mason, W. P., Chinnaiyan, P., Butowski, N., Groves, M. D., Kesari, S., Freedman, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1540 · Cited by 318
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 285
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Schott, A. F., Landis, M. D., Dontu, G., Griffith, K. A., Layman, R. M., Krop, I., Paskett, L. A., Wong, H., Dobrolecki, L. E., Lewis, M. T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3326 · Cited by 277
Evidence for the direct involvement of βTrCP in Gli3 protein processing
Wang, B., & Li, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509927103 · Cited by 273
A Monoclonal Antibody against Wnt-1 Induces Apoptosis in Human Cancer Cells
He, B., You, L., Uematsu, K., Xu, Z., Lee, A. Y., Matsangou, M., McCormick, F., & Jablons, D. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80048-4 · Cited by 269
Tolcher, A. W., Messersmith, W. A., Mikulski, S. M., Papadopoulos, K. P., Kwak, E. L., Gibbon, D. G., Patnaik, A., Falchook, G. S., Dasari, A., Shapiro, G. I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8282 · Cited by 268
Self-citationTargeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells
Teng, Y., Wang, X., Wang, Y., & Ma, D. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.028 · Cited by 250
Fujii, N., You, L., Xu, Z., Uematsu, K., Shan, J., He, B., Mikami, I., Edmondson, L. R., Neale, G., Zheng, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2726 · Cited by 232
Wnt Stabilization of β-Catenin Reveals Principles for Morphogen Receptor-Scaffold Assemblies
Kim, S.-E., Huang, H., Zhao, M., Zhang, X., Zhang, A., Semonov, M. V., MacDonald, B. T., Zhang, X., Abreu, J. G., Peng, L., et al. (2013) · Science · doi:10.1126/science.1232389 · Cited by 230
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
Zebisch, M., Xu, Y., Krastev, C., MacDonald, B. T., Chen, M., Gilbert, R. J. C., He, X., & Jones, E. Y. (2013) · Nature Communications · doi:10.1038/ncomms3787 · Cited by 217
Jimeno, A., Gordon, M., Chugh, R., Messersmith, W., Mendelson, D., Dupont, J., Stagg, R., Kapoun, A. M., Xu, L., Uttamsingh, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2157 · Cited by 209
Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled
Grandy, D., Shan, J., Zhang, X., Rao, S., Akunuru, S., Li, H., Zhang, Y., Alpatov, I., Zhang, X. A., Lang, R. A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.009647 · Cited by 201
Wnt–Notch signalling crosstalk in development and disease
Collu, G. M., Hidalgo-Sastre, A., & Brennan, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1644-x · Cited by 198
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
Nagaraj, A. B., Joseph, P., Kovalenko, O., Singh, S., Armstrong, A., Redline, R., Resnick, K., Zanotti, K., Waggoner, S., & DiFeo, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4690 · Cited by 195
Jiang, X., Charlat, O., Zamponi, R., Yang, Y., & Cong, F. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.03.015 · Cited by 193
The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways
Borggrefe, T., Lauth, M., Zwijsen, A., Huylebroeck, D., Oswald, F., & Giaimo, B. D. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.020 · Cited by 192
Wnt/β-Catenin Signaling Induces the Expression and Activity of βTrCP Ubiquitin Ligase Receptor
Spiegelman, V. S., Slaga, T. J., Pagano, M., Minamoto, T., Ronai, Z., & Fuchs, S. Y. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80327-5 · Cited by 187
Arqués, O., Chicote, I., Puig, I., Tenbaum, S. P., Argilés, G., Dienstmann, R., Fernández, N., Caratù, G., Matito, J., Silberschmidt, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3081 · Cited by 178
Croce, J. C., & McClay, D. R. (2008) · Methods in Molecular Biology · doi:10.1007/978-1-60327-469-2_1 · Cited by 177
Safely targeting cancer stem cells via selective catenin coactivator antagonism
Lenz, H., & Kahn, M. (2014) · Cancer Science · doi:10.1111/cas.12471 · Cited by 175
Gamma secretase inhibitors of Notch signaling
Osipo, C., Zlobin, & Olsauskas-Kuprys (2013) · OncoTargets and Therapy · doi:10.2147/ott.s33766 · Cited by 174
Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis
Okamoto, M., Udagawa, N., Uehara, S., Maeda, K., Yamashita, T., Nakamichi, Y., Kato, H., Saito, N., Minami, Y., Takahashi, N., et al. (2014) · Scientific Reports · doi:10.1038/srep04493 · Cited by 166
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R. D., Landen, C. N., Straughn, J. M., & Buchsbaum, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.005 · Cited by 161
Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3 -mutant neoplasia
Koo, B.-K., van Es, J. H., van den Born, M., & Clevers, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508113112 · Cited by 158
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., Cain, J., Tam, R., Cheng, C.-Y., Evans, J., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700090 · Cited by 155
The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis
Staal, F. J. T., & Sen, J. M. (2008) · European Journal of Immunology · doi:10.1002/eji.200738118 · Cited by 140
Tian, X., Hou, W., Fang, Y., Fan, J., Tong, H., Bai, S., Qu, C., Xu, H. J., & Li, Y. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-100 · Cited by 125
Säfholm, A., Tuomela, J. M., Rosenkvist, J., Dejmek, J. S., Härkönen, P. L., & Andersson, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0711 · Cited by 124
Papayannidis, C., DeAngelo, D. J., Stock, W., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., Ozeck, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.80 · Cited by 122
Suppressor of Fused Negatively Regulates β-Catenin Signaling
Meng, X., Poon, R. W. M., Zhang, X., Cheah, A. Y. L., Ding, Q., Hui, C., & Alman, B. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105317200 · Cited by 119
Li, S., Li, Z., Liu, W., & Zhao, M. (2015) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972215 · Cited by 119
Gandhirajan, R. K., Staib, P., Minke, K., Gehrke, I., Plickert, G., Schlösser, A., Schmitt, E. K., Hallek, M. J., & Kreuzer, K. (2010) · Neoplasia · doi:10.1593/neo.91972 · Cited by 117
The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Arensman, M. D., Telesca, D., Lay, A. R., Kershaw, K. M., Wu, N., Donahue, T. R., & Dawson, D. W. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1005 · Cited by 114
Jesus‐Acosta, A. D., Laheru, D. A., Maitra, A., Arcaroli, J. J., Rudek, M. A., Dasari, A. N., Blatchford, P. J., Quackenbush, K. S., & Messersmith, W. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0083-8 · Cited by 111
Holmen, S. L., Salic, A. N., Diegel, C. R., Kirschner, M. W., & Williams, B. O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204989200 · Cited by 109
Targeting GLI factors to inhibit the Hedgehog pathway
Infante, P., Alfonsi, R., Botta, B., Mori, M., & Marcotullio, L. D. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.05.006 · Cited by 107
The Development of Highly Potent Inhibitors for Porcupine
Wang, X., Moon, J., Dodge, M. E., Pan, X., Zhang, L.-S., Hanson, J., Tuladhar, R., Ma, Z., Shi, H., Williams, N. S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400159c · Cited by 107
Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1
Zhong, Y., Katavolos, P., Nguyen, T., Lau, T., Boggs, J. W., Sambrone, A., Kan, D., Merchant, M. A., Harstad, E. B., Diaz, D., et al. (2015) · Toxicologic Pathology · doi:10.1177/0192623315621192 · Cited by 107
Ma, L., Wang, X., Jia, T., Wei, W., Chua, M., & So, S. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4455 · Cited by 106
Hallett, R. M., Kondratyev, M. K., Giacomelli, A. O., Nixon, A. M. L., Girgis-Gabardo, A., Ilieva, D., & Hassell, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033976 · Cited by 102
Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer
Masuda, M., Sawa, M., & Yamada, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.009 · Cited by 97
Yao, J., & Qian, C. (2009) · Medical Oncology · doi:10.1007/s12032-009-9326-5 · Cited by 95
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
Steg, A. D., Katre, A. A., Bevis, K. S., Ziebarth, A., Dobbin, Z. C., Shah, M. M., Alvarez, R. D., & Landen, C. N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1058 · Cited by 90
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10
Fukukawa, C., Hanaoka, H., Nagayama, S., Tsunoda, T., Toguchida, J., Endo, K., Nakamura, Y., & Katagiri, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00701.x · Cited by 82
Smith, D. C., Rosen, L. S., Chugh, R. K., Goldman, J. W., Xu, L., Kapoun, A. M., Brachmann, R. K., Dupont, J., Stagg, R., Tolcher, A. W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2540 · Cited by 81
β-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression
Schade, B., Lesurf, R., Sanguin‐Gendreau, V., Bui, T., Deblois, G., O’Toole, S. A., Millar, E. K. A., Zardawi, S. J., López‐Knowles, E., Sutherland, R. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3925 · Cited by 80
Canesin, G., Axelsson, S. E., Hellsten, R., Krzyzanowska, A., Prasad, C. P., Bjartell, A. S., & Andersson, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184418 · Cited by 80
Piha-Paul, S. A., Münster, P. N., Hollebecque, A., Argilés, G., Dajani, O. F., Cheng, J., Wang, R., Swift, A., Tosolini, A., & Gupta, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.115 · Cited by 75
Loregger, A., Grandl, M., Mejías‐Luque, R., Allgäuer, M., Degenhart, K., Haselmann, V., Oikonomou, C., Hatzis, P., Janssen, K., Nitsche, U., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac6757 · Cited by 75
XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis
Zhan, P., Wang, Q., Qian, Q., & Yu, L. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-1 · Cited by 72
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
Pozzi, S., Fulciniti, M., Yan, H., Vallet, S., Eda, H., Patel, K. J., Santo, L., Cirstea, D. D., Hideshima, T., Schirtzinge, L., et al. (2013) · Bone · doi:10.1016/j.bone.2013.01.012 · Cited by 71
Ko, A. H., Chiorean, E. G., Kwak, E. L., Lenz, H., Nadler, P. I., Wood, D. L., Fujimori, M., Inada, T., Kouji, H., & McWilliams, R. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e15721 · Cited by 69
Li, B., Flaveny, C. A., Giambelli, C., Fei, D. L., Han, L., Hang, B. I., Bai, F., Pei, X., Nosé, V., Burlingame, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101969 · Cited by 67
Stratford, E. W., Daffinrud, J., Munthe, E., Castro, R., Waaler, J., Krauss, S. J. K., & Myklebost, O. (2013) · Cancer Medicine · doi:10.1002/cam4.170 · Cited by 64
Mo, M., Li, M.-R., Zhao, C., Liu, X.-W., Sheng, Q., & Hai‐Meng, Z. H. O. U. (2013) · Oncology Letters · doi:10.3892/ol.2013.1256 · Cited by 63
Gβγ Activates GSK3 to Promote LRP6-Mediated β-Catenin Transcriptional Activity
Jernigan, K. K., Cselenyi, C. S., Thorne, C. A., Hanson, A. J., Tahinci, E., Hajicek, N., Oldham, W. M., Lee, L. A., Hamm, H. E., Hepler, J. R., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000647 · Cited by 58
Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling
Aberger, F., Hutterer, E., Sternberg, C., del Burgo, P. J., & Hartmann, T. N. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0163-4 · Cited by 56
Efficacy of Wnt-1 monoclonal antibody in sarcoma cells
Mikami, I., You, L., He, B., Xu, Z., Batra, S., Lee, A. Y., Mazières, J., Reguart, N., Uematsu, K., Koizumi, K., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-53 · Cited by 52
Jenkins, D. W., Ross, S. J., Veldman-Jones, M. H., Foltz, I. N., Clavette, B. C., Manchulenko, K., Eberlein, C., Kendrew, J., Petteruti, P., Cho, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1027 · Cited by 52
Zweidler-McKay, P. A., DeAngelo, D. J., Douer, D., Dombret, H., Ottmann, O. G., Vey, N., Thomas, D. A., Zhu, L., Huang, F., Bajaj, G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.968.968 · Cited by 46
McWilliams, R. R., Ko, A. H., Chiorean, E. G., Kwak, E. L., Lenz, H., Nadler, P. I., Wood, D. L., Fujimori, M., Morita, K., Inada, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e15270 · Cited by 44
Wnt5a Controls Notch1 Signaling through CaMKII-mediated Degradation of the SMRT Corepressor Protein
Ann, E., Kim, H., Seo, M., Mo, J., Kim, M., Yoon, J., Ahn, J., & Park, H.-S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.356048 · Cited by 40
Synthesis of Potent Dishevelled PDZ Domain Inhibitors Guided by Virtual Screening and NMR Studies
Shan, J., Zhang, X., Bao, J., Cassell, R. J., & Zheng, J. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01295.x · Cited by 39
Giefing, M., Wierzbicka, M., Szyfter, K., Brenner, J. C., Braakhuis, B. J. M., Brakenhoff, R. H., Bradford, C. R., Sørensen, J. A., Rinaldo, A., Rodrigo, J. P., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.10.070 · Cited by 33
Cortes, J. E., Faderl, S. H., Pagel, J. M., Jung, C. W., Yoon, S., Koh, Y., Pardanani, A. D., Hauptschein, R. S., Lee, K.-J., & Lee, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.7044 · Cited by 32
The inhibition of Wnt/β-catenin signaling pathway in human colon cancer cells by sulindac.
Tai, W.-P., Hu, P., Wu, J., & Lin, X.-C. (2014) · PubMed · doi:10.1700/1430.15823 · Cited by 24
Yeung, P., Beviglia, L., Cancilla, B., Dee-Hoskins, C., Evans, J., Fischer, M. M., Yen, W.-C., Gurney, A. L., Lewicki, J. A., Hoey, T. C., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1907 · Cited by 20
Schneider, P. N., Slusarski, D. C., & Houston, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044096 · Cited by 15
Weekes, C. D., Berlin, J. D., Lenz, H., O’Neil, B. H., Messersmith, W. A., Cohen, S., Dendinger, C., Shahda, S., Kapoun, A. M., Zhang, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw368.10 · Cited by 12
Teneggi, V., NG, M. M., Tan, D. S. P., Subbiah, V., Weekes, C. D., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., et al. (2016) · Annals of Oncology · doi:10.1016/s0923-7534(21)00310-0 · Cited by 10
Teneggi, V., Ng, M., Tan, D. S., Subbiah, V., Weekes, C., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw579.004 · Cited by 8
Patnaik, A., LoRusso, P. M., Münster, P. N., Tolcher, A. W., Davis, S. L., Heymach, J. V., Ferraroto, R., Xu, L., Kapoun, A. M., Faoro, L. N., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70128-5 · Cited by 2
Hung, H. T., Ong, R., Puehler, F., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2276 · Cited by 2
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Metadata
- Authors
- Krishnamurthy, N., & Kurzrock, R.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 62
- Pages
- 50-60
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2771031544
- Cited by
- 1,026
- References
- 96
- FWCI
- 31.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.